Methionine Restriction: Ready for Prime Time in the Cancer Clinic?
Methionine Restriction: Ready for Prime Time in the Cancer Clinic?
复制标题
蛋氨酸限制：准备好迎接癌症诊所的黄金时段了吗？
作者：
Jun Yamamoto;Qinghong Han;Mark Simon;Daniel Thomas;R. Hoffman
至少从 100 年前的瓦尔堡时代开始，人们就已经在临床上尝试选择性地饥饿癌症。限制热量或低碳水化合物饮食对癌症患者的成功有限。限制蛋氨酸是选择性饥饿癌细胞的另一种策略，因为与正常细胞不同，癌症对蛋氨酸上瘾。癌症的蛋氨酸成瘾被称为霍夫曼效应。过去半个世纪的大量临床前研究表明，蛋氨酸限制对所有主要癌症类型都非常有效，并且与化疗具有协同作用。低蛋氨酸医疗饮食可以有效降低蛋氨酸，并已显示出一些临床前景，但它们不好吃，因此不可持续。然而，选择性地选择植物性食物可以实现各种可持续的低蛋氨酸饮食。我们的实验室开发了一种可以口服作为补充剂的蛋氨酸酶，并在晚期癌症患者中取得了积极的结果，包括激素非依赖性前列腺癌和其他顽固性癌症。问题是通过低蛋氨酸饮食限制蛋氨酸，或者通过蛋氨酸酶进一步限制蛋氨酸与低蛋氨酸饮食相结合，是否已经准备好在临床上发挥作用，特别是与其他协同疗法相结合。这个问题有望在不久的将来得到解答，特别是对于所有标准治疗均失败的晚期癌症患者。
Attempts to selectively starve cancers in the clinic have been made at least since the time of Warburg beginning 100 years ago. Calorie-restriction or low-carbohydrate diets have had limited success with cancer patients. Methionine restriction is another strategy to selectively starve cancer cells, since cancers are addicted to methionine, unlike normal cells. Methionine addiction of cancer is termed the Hoffman effect. Numerous preclinical studies over the past half century have shown methionine restriction to be highly effective against all major cancer types and synergistic with chemotherapy. Low-methionine medical diets can be effective in lowering methionine and have shown some clinical promise, but they are not palatable and thereby not sustainable. However, selectively choosing among plant-based foods allows a variety of low-methionine diets that are sustainable. Our laboratory has developed a methioninase that can be administered orally as a supplement and has resulted in anecdotal positive results in patients with advanced cancer, including hormone-independent prostate cancer, and other recalcitrant cancers. The question is whether methionine restriction through a low-methionine diet, or even greater methionine restriction with methioninase in combination with a low-methionine diet, is ready for prime time in the clinic, especially in combination with other synergistic therapy. The question will hopefully be answered in the near future, especially for advanced cancer patients who have failed all standard therapy.
登录
查看更多内容
影响因子：
11.2
作者：
D. Kokkinakis;Robert M. Hoffman;Eugene P. Frenkel;Jacquelynn B. Wick;Qinghong Han;Mingxu Xu;Yuying Tan;S. Schold
通讯作者：
D. Kokkinakis;Robert M. Hoffman;Eugene P. Frenkel;Jacquelynn B. Wick;Qinghong Han;Mingxu Xu;Yuying Tan;S. Schold
DOI：
10.1073/pnas.77.12.7306
发表时间：
1980-01-01
期刊：
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES
影响因子：
--
作者：
HOFFMAN, RM;JACOBSEN, SJ
通讯作者：
JACOBSEN, SJ
DOI：
10.1016/0006-291x(83)91218-4
发表时间：
1983-01-01
影响因子：
3.1
作者：
MECHAM, JO;ROWITCH, D;HOFFMAN, RM
通讯作者：
HOFFMAN, RM
影响因子：
10.3
作者：
STERN, PH;HOFFMAN, RM
通讯作者：
HOFFMAN, RM